| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40259-016-0168-3 |
| P698 | PubMed publication ID | 27023706 |
| P50 | author | Genevieve Evin | Q89079991 |
| P2093 | author name string | Genevieve Evin | |
| P2860 | cites work | 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study | Q37699953 |
| Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. | Q37779109 | ||
| Genetics of Alzheimer's disease: new evidences for an old hypothesis? | Q37849427 | ||
| Amyloid precursor protein processing and Alzheimer's disease | Q37860317 | ||
| BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity | Q37876434 | ||
| The physiology of the β-amyloid precursor protein intracellular domain AICD. | Q37961985 | ||
| The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes | Q37979641 | ||
| Transcriptional and post-transcriptional regulation of β-secretase. | Q38062499 | ||
| The amyloid precursor protein: a biochemical enigma in brain development, function and disease | Q38107684 | ||
| Tau immunotherapy and imaging. | Q38136880 | ||
| The evolution of amidine-based brain penetrant BACE1 inhibitors | Q38202365 | ||
| Molecular mechanism of intramembrane proteolysis by γ-secretase | Q38238454 | ||
| Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond | Q38257864 | ||
| Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools? | Q38280089 | ||
| Invited review: Neuropathology of tauopathies: principles and practice. | Q38286208 | ||
| Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial | Q38402983 | ||
| Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease | Q38465993 | ||
| Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease | Q38473766 | ||
| Tau and neurodegenerative disease: the story so far. | Q38658752 | ||
| AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans | Q39194419 | ||
| Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE | Q22010705 | ||
| Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease | Q22251067 | ||
| A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 | ||
| Expression analysis of BACE2 in brain and peripheral tissues | Q22253458 | ||
| The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate | Q24291471 | ||
| Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease | Q24298408 | ||
| TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity | Q24321405 | ||
| Amyloid plaque core protein in Alzheimer disease and Down syndrome | Q24568384 | ||
| Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients | Q24633400 | ||
| BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein | Q24675964 | ||
| Synapses and Alzheimer's disease | Q26269868 | ||
| The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events | Q26781635 | ||
| Neurodegeneration and microtubule dynamics: death by a thousand cuts | Q26781649 | ||
| Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers | Q26825442 | ||
| The genetics and neuropathology of Alzheimer's disease | Q26998097 | ||
| Neuropathological alterations in Alzheimer disease | Q27003314 | ||
| The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes | Q27026919 | ||
| Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines | Q27320084 | ||
| MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease. | Q27327525 | ||
| Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor | Q27627346 | ||
| Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands | Q27644439 | ||
| Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease | Q27674362 | ||
| Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor | Q27675616 | ||
| Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides | Q27685417 | ||
| The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans | Q27697610 | ||
| Immunotherapeutic approaches for Alzheimer's disease | Q28081278 | ||
| Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity | Q37357625 | ||
| High activities of BACE1 in brains with mild cognitive impairment | Q37415435 | ||
| A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease | Q37465017 | ||
| Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease | Q37519725 | ||
| An atomic structure of human γ-secretase | Q28116260 | ||
| Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 | ||
| Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1 | Q28139001 | ||
| Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease | Q28140038 | ||
| A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain | Q28141707 | ||
| BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics | Q28201876 | ||
| A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60 | Q28205099 | ||
| Alzheimer's disease-do tauists and baptists finally shake hands? | Q28215968 | ||
| Control of peripheral nerve myelination by the beta-secretase BACE1 | Q28264800 | ||
| Additional mechanisms conferring genetic susceptibility to Alzheimer's disease | Q28391511 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity | Q29616491 | ||
| The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor | Q29618322 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice | Q30493115 | ||
| Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice | Q30497942 | ||
| Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes | Q30530899 | ||
| Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data | Q30584453 | ||
| Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839. | Q30830349 | ||
| Imaging endpoints for clinical trials in Alzheimer's disease | Q30885979 | ||
| The beta-secretase, BACE: a prime drug target for Alzheimer's disease | Q32061148 | ||
| Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation | Q32063777 | ||
| Neuropathology of Alzheimer's disease | Q33526568 | ||
| Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor | Q33558208 | ||
| Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology | Q33808402 | ||
| Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms | Q33835683 | ||
| The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region | Q33890879 | ||
| ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site | Q33925646 | ||
| Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial | Q33988701 | ||
| Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate | Q34014078 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study | Q34279689 | ||
| Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production | Q34280406 | ||
| Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
| The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. | Q39755143 | ||
| Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers. | Q39809741 | ||
| Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease | Q39813744 | ||
| Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo | Q40199218 | ||
| Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation | Q40601680 | ||
| A non-amyloidogenic function of BACE-2 in the secretory pathway | Q40725025 | ||
| L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity | Q40865987 | ||
| The gene defects responsible for familial Alzheimer's disease | Q41288332 | ||
| Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies | Q41322553 | ||
| Cooperative roles of hydrophilic loop 1 and the C-terminus of presenilin 1 in the substrate-gating mechanism of γ-secretase. | Q41447351 | ||
| Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules | Q41526761 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models | Q42231018 | ||
| Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass | Q42726932 | ||
| Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles | Q42768388 | ||
| Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain | Q43516537 | ||
| Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease. | Q43667985 | ||
| A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity | Q43793656 | ||
| Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines | Q44033487 | ||
| Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease | Q44060098 | ||
| Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease | Q44132132 | ||
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 | ||
| Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design | Q44704283 | ||
| Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models | Q45021910 | ||
| Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. | Q45908140 | ||
| Processing of beta-amyloid precursor protein by cathepsin D. | Q46549381 | ||
| Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice | Q46574998 | ||
| Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds | Q46922754 | ||
| An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. | Q47393680 | ||
| Structure-guided design of β-secretase (BACE-1) inhibitors | Q48091068 | ||
| Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis | Q48217048 | ||
| Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab | Q48852013 | ||
| 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease | Q50440639 | ||
| Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease | Q50657023 | ||
| Vaccine development for Alzheimer's disease: a shot of good news. | Q52019724 | ||
| Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. | Q53158136 | ||
| Candidate .gamma.-Secretases in the Generation of the Carboxyl Terminus of the Alzheimer's Disease .beta.A4 Amyloid: Possible Involvement of Cathepsin D | Q53200409 | ||
| A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity. | Q53220934 | ||
| Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD? | Q53369812 | ||
| Bace1 modulates myelination in the central and peripheral nervous system. | Q53588736 | ||
| The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease | Q56566644 | ||
| Alzheimer's disease risk genes and mechanisms of disease pathogenesis | Q34425904 | ||
| Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor | Q34475374 | ||
| The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus | Q34477111 | ||
| Reduced sodium channel Na(v)1.1 levels in BACE1-null mice | Q34624269 | ||
| BACE inhibitors as potential therapeutics for Alzheimer's disease | Q34655697 | ||
| Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein | Q34684198 | ||
| Immunological approaches as therapy for Alzheimer's disease | Q35040852 | ||
| Axonal and Schwann cell BACE1 is equally required for remyelination of peripheral nerves | Q35142894 | ||
| Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease | Q35540628 | ||
| Developing β-secretase inhibitors for treatment of Alzheimer's disease | Q35746998 | ||
| η-Secretase processing of APP inhibits neuronal activity in the hippocampus | Q35760228 | ||
| The gamma-secretase complex: machinery for intramembrane proteolysis | Q35803148 | ||
| Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors | Q35876179 | ||
| The mechanism of γ-Secretase dysfunction in familial Alzheimer disease | Q36000134 | ||
| Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials | Q36005648 | ||
| A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice | Q36027275 | ||
| Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons | Q36103683 | ||
| The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo | Q36122127 | ||
| Qualitative changes in human γ-secretase underlie familial Alzheimer's disease | Q36286058 | ||
| β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment | Q36379519 | ||
| TRPC6 specifically interacts with APP to inhibit its cleavage by γ-secretase and reduce Aβ production. | Q36417516 | ||
| BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease | Q36427048 | ||
| Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease | Q36459592 | ||
| The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation | Q36562023 | ||
| A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat | Q36562466 | ||
| Systematic proteomic analysis identifies β-site amyloid precursor protein cleaving enzyme 2 and 1 (BACE2 and BACE1) substrates in pancreatic β-cells | Q36760343 | ||
| Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease | Q36764094 | ||
| BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells | Q36967843 | ||
| AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics | Q37053876 | ||
| Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease | Q37118356 | ||
| Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease | Q37192883 | ||
| A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system | Q37316153 | ||
| Mutations in amyloid precursor protein affect its interactions with presenilin/gamma-secretase | Q37319340 | ||
| BACE1 regulates voltage-gated sodium channels and neuronal activity | Q37355641 | ||
| P433 | issue | 3 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 173-194 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | BioDrugs | Q4914612 |
| P1476 | title | Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors | |
| P478 | volume | 30 |
| Q39244962 | 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927. |
| Q42655757 | Alzheimer's disease drug development pipeline: 2017. |
| Q33612147 | An Overview of the Protective Effects of Chitosan and Acetylated Chitosan Oligosaccharides against Neuronal Disorders |
| Q38797428 | Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease |
| Q88839412 | C5-C6 Carbocyclic-Fused Iminothiadiazine Dioxides as BACE Inhibitors, Their Compositions, and Their Use |
| Q100474284 | Cognitive screening for early detection of mild cognitive impairment |
| Q33665730 | Docking Studies and Biological Evaluation of a Potential β-Secretase Inhibitor of 3-Hydroxyhericenone F from Hericium erinaceus |
| Q64932312 | Gram-Scale Synthesis of a β-Secretase 1 (BACE 1) Inhibitor. |
| Q42370702 | Identification and characterization of new isoforms of human fas apoptotic inhibitory molecule (FAIM). |
| Q47565168 | In silico ligand-based modeling of hBACE-1 inhibitors. |
| Q57295377 | Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design |
| Q50534589 | Longitudinal Modeling of Functional Decline Associated with Pathologic Alzheimer's Disease in Older Persons without Cognitive Impairment |
| Q97539357 | Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain |
| Q47625268 | Population density analysis for determining the protonation state of the catalytic dyad in BACE1-tertiary carbinamine-based inhibitor complex |
| Q42651967 | Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport |
| Q38864839 | Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease |
| Q91962329 | Rapid Identification of Tanshinone IIA Metabolites in an Amyloid-β1-42 Induced Alzherimer's Disease Rat Model using UHPLC-Q-Exactive Qrbitrap Mass Spectrometry |
| Q89507507 | Synthesis, Molecular Docking, and Preliminary Evaluation of 2-(1,2,3-Triazoyl)benzaldehydes As Multifunctional Agents for the Treatment of Alzheimer's Disease |
Search more.